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complications was assessed for the last six months.
RESULTS: CODIP patients totaling 79.3% had at least
one complication, 21.7% having microvascular only,
17.5% macrovascular only, 40% having both microvas-
cular and macrovascular complications. The prevalence
of microvascular complications: foot ulcer 6.9% (ampu-
tations performed in 2.6%), 1-eye retinopathy 7.3%,
both-eyes 17.2%, photocoagulation 9.9%, vitrectomy
1.7%, microalbuminuria 19.1%, manifested nephropa-
thy 11.9%, dialysis 0.3%, neuropathy 41.9%. The preva-
lence of macrovascular complications: coronary artery
disease 42.6% (unstable angina 4.9%), myocardial
infarction 14.2%, heart failure 15.5%, PTCA 2.3%,
CABG 3.0%, TIA 5.0%, PAD 30.7%. Mean cost, in 6
months observations, for patients with no complica-
tions amounted to €498 (PPP value: €1 = 1.9 PLN). Cost
impact factor for microvascular only, macrovascular only
and microvascular and macrovascular, as compared to
patients with no complications were estimated at 1.54,
1.52, and 2.02, respectively. CONCLUSIONS: Compli-
cations have a substantial impact on direct cost of dia-
betes type 2.
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OBJECTIVES: In 2000 an electronic prescription service
called “Homecare” was established in the Local Health
Unit (LHU; 920.196 inhabitants) of Legnano (Italy) in
order to manage the distribution of devices for diabetes
care directly through private pharmacies. The objective
was to evaluate if the allocation of the medical products
through “Homecare-Legnano” resulted in savings to the
LHU. METHODS: We created an “Index of Saving” (IS),
calculated as the ratio between the difference from actual
and budgeted and budgeted: IS = [(actual - budgeted)/
budgeted], in which “budgeted” is the number of devices
that each patient can theoretically receive every month
and “actual” is the number of devices that each patient
actually received. The IS value ranged from +1 to 0 and
can be interpreted as the percentage saving obtained in
the allocation of medical products for the LHU system.
We performed an economic evaluation of the savings, in
monetary terms for medical products, paid out through
“Homecare” for the period January to December 2001.
To verify if the savings, both in physical (IS) terms and in
monetary terms were signiﬁcantly different from 0, we
conducted a statistical analysis using a “Student t” test.
RESULTS: More than 17,000 patients used the Home-
care service through the 197 private pharmacies, which
were involved in the project. Twenty different types 
of medical products were distributed for a total of
2,668,582 devices. The mean value of IS for medical
products per month was -0.134, i.e. a saving in the allo-
cation of medical products of 13.4%. This value was sig-
niﬁcantly different from 0 (CI 95% -0.1585; -0.1101 
P < 0.0001) corresponding to a monetary saving of
€29.74 per patient-year. CONCLUSIONS: The “Home-
care Legnano” programme simpliﬁed the procedures for
allocation of diabetic medical products and simultane-
ously resulted in savings in monetary terms for the LHU.
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OBJECTIVES: To estimate the cost per quality adjusted
life year (QALY) with insulin glargine (LANTUS) com-
pared with NPH insulin in the treatment of patients with
Type 1 diabetes in Norway. An impediment to adequate
management of patients with Type 1 diabetes has been
maintaining an appropriate balance between adequate
glycaemic control and the risk of hypoglycaemia, which
may have a serious impact on quality of life. The ratio-
nale behind insulin glargine therapy is to facilitate this
trade-off by improving the probability of reaching gly-
caemic control targets, reducing frequency of hypo-
glycaemia (FoH), or both. METHODS: The model
(developed by Aventis Pharma) estimates the cost-utility
of insulin glargine versus NPH insulin over 9 years in
Norway. The yearly frequency of microvascular compli-
cations for NPH insulin treatment is based on data from
the DCCT. For insulin glargine, the effects on HbA1c
observed in clinical trials are used to estimate complica-
tion rates based on the relationship observed in the
DCCT. Estimates of QALYs lost are based on complica-
tion rates and frequencies of serious hypoglycaemic
events, and the impact on QALYs due to fear of hypo-
glycaemia (proportional to the frequency of events) is also
modelled. The cost perspective is societal, and Norwegian
costs of treatments and complications are utilized.
RESULTS: Under base-case assumptions (DHbA1c =
0.4%, DFoH = 15 events/patient—year, discount-rate
3%) the marginal cost/QALY is NOK 3700. Sensitivity
analyses based on the central parameters indicate the
analysis is stable. Even under conservative assumptions
(DHbA1c = 0.2% and a 60% reduction in the impact 
of fear of hypoglycaemia) the incremental cost/QALY
remains acceptable at < NOK 23,000. CONCLUSIONS:
Based on the assumptions in this model, the results indi-
cate that insulin glargine is a cost-effective alternative to
NPH insulin in patients with Type 1 diabetes.
